FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Vaccine2013; 31(45); 5216-5222; doi: 10.1016/j.vaccine.2013.08.083

Humoral response and antiviral cytokine expression following vaccination of thoroughbred weanlings–a blinded comparison of commercially available vaccines.

Abstract: Previous studies in experimental ponies using interferon gamma (IFN-γ) as a marker for cell mediated immune (CMI) response demonstrated an increase in IFN-γ gene expression following vaccination with an ISCOM subunit, a canarypox recombinant and more recently, an inactivated whole virus vaccine. The objective of this study was to carry out an independent comparison of both humoral antibody and CMI responses elicited following vaccination with all these vaccine presentation systems. Antibody response of 44 Thoroughbred weanlings was monitored for three weeks following the second dose of primary vaccination (V2) by single radial haemolysis (SRH). The pattern of antibody response was similar for all vaccines. The antibody response of horses vaccinated with the inactivated whole virus vaccine (Duvaxyn IE-T Plus) was superior to that of the horses vaccinated with the ISCOM-matrix subunit (Equilis Prequenza Te) and canarypox recombinant (ProteqFlu-Te) vaccine. In this study 39% of weanlings failed to seroconvert following their first dose of primary vaccination (V1). Poor response to vaccination (H3N8) was observed among weanlings vaccinated with Equilis Prequenza Te and ProteqFlu-Te but not among those vaccinated with Duvaxyn IE-T Plus. PAXgene bloods were collected on days 0, 2, 7 and 14 following V1. Gene expression levels of IFN-γ, IL-1β (proinflammatory cytokine) and IL-4 (B cell stimulating cytokine) were measured using RT-PCR. Mean gene expression levels of IL-1β and IL-4 peaked on day 14 post vaccination. The increase in IL-4 gene expression by horses vaccinated with Equilis Prequenza Te was significantly greater to those vaccinated with the other two products. Vaccination with all three vaccines resulted in a significant increase in IFN-γ gene expression which peaked at 7 days post V1. Overall, there was no significant difference in IFN-γ gene expression by the horses vaccinated with the whole inactivated, the subunit and the canarypox recombinant vaccines included in this study.
Copyright © 2013. Published by Elsevier Ltd.
Get Full Text
Publication Date: 2013-09-08 PubMed ID: 24021309DOI: 10.1016/j.vaccine.2013.08.083Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Comparative Study
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The study compares three different vaccines in terms of their ability to provoke both humoral (antibody) and cell mediated immune responses in thoroughbred weanlings. Results showed that, while the inactivated whole virus vaccine produced the best antibody response, all three vaccines were effective in stimulating immune responses to a significant degree.

Objective of the Study

  • The research aimed to make an unbiased comparison of humoral and Cell-Mediated Immune (CMI) responses triggered after vaccination using ISCOM subunit, canarypox recombinant, and an inactivated whole virus vaccine.

Vaccines Used in the Study

  • Three different types of vaccines were used: an inactivated whole virus vaccine (Duvaxyn IE-T Plus), ISCOM-matrix subunit (Equilis Prequenza Te), and a canarypox recombinant vaccine (ProteqFlu-Te).

Humoral Response to Vaccination

  • The antibody response of thoroughbred weanlings was monitored for three weeks following the second dose of primary vaccination by Single Radial Haemolysis (SRH).
  • All the vaccines triggered similar patterns of antibody response.
  • The inactivated whole virus vaccine stimulated a superior antibody response compared to the ISCOM-matrix subunit and canarypox recombinant vaccine.
  • About 39% of weanlings did not show a surge in antibodies after the first vaccination.
  • A poorer response was observed among weanlings vaccinated with Equilis Prequenza Te and ProteqFlu-Te compared to those vaccinated with Duvaxyn IE-T Plus.

Cell-Mediated Immune (CMI) Response to Vaccination

  • Blood samples were collected on different days post vaccination to monitor the expression levels of IFN-γ, IL-1β (a proinflammatory cytokine), and IL-4 (a B cell stimulating cytokine).
  • The expression levels of IL-1β and IL-4 peaked on day 14 after vaccination.
  • Horses vaccinated with Equilis Prequenza Te showed a significantly higher increase in IL-4 gene expression compared to those vaccinated with the other two vaccines.
  • All three vaccines resulted in a significant increase in IFN-γ gene expression, peaking at 7 days post vaccination.
  • No significant difference was observed in IFN-γ gene expression among the horses vaccinated with the whole inactivated, the subunit, and the canarypox recombinant vaccines.

Conclusions

  • While the inactivated whole virus vaccine triggered the best antibody response, all three vaccines were effective in provoking immune responses to a significant degree. This implies that all three vaccination systems can potentially be effective in battling diseases in the weanlings.

Cite This Article

APA
Gildea S, Quinlivan M, Murphy BA, Cullinane A. (2013). Humoral response and antiviral cytokine expression following vaccination of thoroughbred weanlings–a blinded comparison of commercially available vaccines. Vaccine, 31(45), 5216-5222. https://doi.org/10.1016/j.vaccine.2013.08.083

Publication

Vaccine
ISSN: 1873-2518
NlmUniqueID: 8406899
Country: Netherlands
Language: English
Volume: 31
Issue: 45
Pages: 5216-5222
PII: S0264-410X(13)01195-X

Researcher Affiliations

Gildea, Sarah
  • Virology Unit, The Irish Equine Centre, Johnstown, Naas, Co., Kildare, Ireland.
Quinlivan, Michelle
    Murphy, Barbara A
      Cullinane, Ann

        MeSH Terms

        • Animals
        • Antibodies, Viral / blood
        • Cytokines / biosynthesis
        • Gene Expression Profiling
        • Horse Diseases / immunology
        • Horse Diseases / prevention & control
        • Horses
        • Influenza A Virus, H3N8 Subtype / immunology
        • Influenza Vaccines / administration & dosage
        • Influenza Vaccines / immunology
        • Orthomyxoviridae Infections / prevention & control
        • Orthomyxoviridae Infections / veterinary
        • Vaccination / methods
        • Vaccines, Inactivated / administration & dosage
        • Vaccines, Inactivated / immunology
        • Vaccines, Subunit / administration & dosage
        • Vaccines, Subunit / immunology
        • Vaccines, Synthetic / administration & dosage
        • Vaccines, Synthetic / immunology

        Citations

        This article has been cited 15 times.
        1. Carnet F, Perrin-Cocon L, Paillot R, Lotteau V, Pronost S, Vidalain PO. An inventory of adjuvants used for vaccination in horses: the past, the present and the future. Vet Res 2023 Mar 2;54(1):18.
          doi: 10.1186/s13567-023-01151-3pubmed: 36864517google scholar: lookup
        2. Tomlinson JE, Van de Walle GR. Nasal transmission of equine parvovirus hepatitis. J Vet Intern Med 2022 Nov;36(6):2238-2244.
          doi: 10.1111/jvim.16569pubmed: 36250682google scholar: lookup
        3. Whitlock F, Grewar J, Newton R. An epidemiological overview of the equine influenza epidemic in Great Britain during 2019. Equine Vet J 2023 Jan;55(1):153-164.
          doi: 10.1111/evj.13874pubmed: 36054725google scholar: lookup
        4. Whitlock F, Murcia PR, Newton JR. A Review on Equine Influenza from a Human Influenza Perspective. Viruses 2022 Jun 15;14(6).
          doi: 10.3390/v14061312pubmed: 35746783google scholar: lookup
        5. El-Hage C, Hartley C, Savage C, Watson J, Gilkerson J, Paillot R. Assessment of Humoral and Long-Term Cell-Mediated Immune Responses to Recombinant Canarypox-Vectored Equine Influenza Virus Vaccination in Horses Using Conventional and Accelerated Regimens Respectively. Vaccines (Basel) 2022 May 26;10(6).
          doi: 10.3390/vaccines10060855pubmed: 35746463google scholar: lookup
        6. Lee DH, Lee EB, Seo JP, Ko EJ. Evaluation of concurrent vaccinations with recombinant canarypox equine influenza virus and inactivated equine herpesvirus vaccines. J Anim Sci Technol 2022 May;64(3):588-598.
          doi: 10.5187/jast.2022.e30pubmed: 35709134google scholar: lookup
        7. Aida V, Pliasas VC, Neasham PJ, North JF, McWhorter KL, Glover SR, Kyriakis CS. Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines. Front Vet Sci 2021;8:654289.
          doi: 10.3389/fvets.2021.654289pubmed: 33937377google scholar: lookup
        8. Pavulraj S, Bergmann T, Trombetta CM, Marchi S, Montomoli E, Alami SSE, Ragni-Alunni R, Osterrieder N, Azab W. Immunogenicity of Calvenza-03 EIV/EHV(®) Vaccine in Horses: Comparative In Vivo Study. Vaccines (Basel) 2021 Feb 17;9(2).
          doi: 10.3390/vaccines9020166pubmed: 33671378google scholar: lookup
        9. Cullinane A, Gahan J, Walsh C, Nemoto M, Entenfellner J, Olguin-Perglione C, Garvey M, Huang Fu TQ, Venner M, Yamanaka T, Barrandeguy M, Fernandez CJ. Evaluation of Current Equine Influenza Vaccination Protocols Prior to Shipment, Guided by OIE Standards. Vaccines (Basel) 2020 Feb 29;8(1).
          doi: 10.3390/vaccines8010107pubmed: 32121419google scholar: lookup
        10. Dilai M, Piro M, El Harrak M, Fougerolle S, Dehhaoui M, Dikrallah A, Legrand L, Paillot R, Fassi Fihri O. Impact of Mixed Equine Influenza Vaccination on Correlate of Protection in Horses. Vaccines (Basel) 2018 Oct 4;6(4).
          doi: 10.3390/vaccines6040071pubmed: 30287762google scholar: lookup
        11. Gildea S, Sanchez Higgins MJ, Johnson G, Walsh C, Cullinane A. Concurrent vaccination against equine influenza and equine herpesvirus - a practical approach. Influenza Other Respir Viruses 2016 Sep;10(5):433-7.
          doi: 10.1111/irv.12396pubmed: 27169603google scholar: lookup
        12. Paillot R. A Systematic Review of Recent Advances in Equine Influenza Vaccination. Vaccines (Basel) 2014 Nov 14;2(4):797-831.
          doi: 10.3390/vaccines2040797pubmed: 26344892google scholar: lookup
        13. Hall SA, Stucke D, Morrone B, Lebelt D, Zanella AJ. Simultaneous detection and quantification of six equine cytokines in plasma using a fluorescent microsphere immunoassay (FMIA). MethodsX 2015;2:241-8.
          doi: 10.1016/j.mex.2015.04.002pubmed: 26150994google scholar: lookup
        14. Gildea S, Fitzpatrick DA, Cullinane A. Epidemiological and virological investigations of equine influenza outbreaks in Ireland (2010-2012). Influenza Other Respir Viruses 2013 Dec;7 Suppl 4(Suppl 4):61-72.
          doi: 10.1111/irv.12192pubmed: 24224821google scholar: lookup
        15. Kumar R, Bera BC, Anand T, Pavulraj S, Kurian Mathew M, Gupta RP, Tripathi BN, Virmani N. Evaluation of immunogenicity and protective efficacy of bacteriophage conjugated haemagglutinin based subunit vaccine against equine influenza virus in a murine model. Vet Res Commun 2024 Jun;48(3):1707-1726.
          doi: 10.1007/s11259-024-10356-6pubmed: 38528300google scholar: lookup
        Subscribe to our newsletter
        Join 99,780 horse owners like you who receive our email updates on horse health and nutrition.